Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ECO 2021 May 10 - 13

Beneficial Effect of Semaglutide 2.4 mg Once Weekly on Patient-Reported Outcome Measures of Weight Related and Health-Related Quality of Life in Adults With Overweight or Obesity in the STEP 1 Trial

Domenica M. Rubino1; Jakob B. Bjorner2; Robert F. Kushner3; Sue D. Pedersen4; Donna H. Ryan5; Marie T.D. Tran6; Lisa von Huth Smith6; Sean Wharton7; Niels Zeuthen6; Ronette L. Kolotkin8;
1Washington Center for Weight Management and Research, Arlington, VA, USA; 2QualityMetric Inc., LLC, Johnston, RI, USA; University of Copenhagen, Copenhagen, Denmark; 3Division of Endocrinology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 4C-ENDO Diabetes and Endocrinology Clinic, Calgary, AB, Canada; 5Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA; 6Novo Nordisk A/S, Soborg, Denmark; 7York University, McMaster University and Wharton Weight Management Clinic, Toronto, ON, Canada; 8Quality of Life Consulting, Durham, NC, USA; Duke Family Medicine and Community Health, Duke University School of Medicine, Durham, NC, USA; Faculty of Health and Social Sciences, Western Norway University of Applied Sciences, Forde, Norway; Centre of Health Research, Forde Hospital Trust, Forde, Norway; Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg, Norway;